Premium
A role for neoadjuvant gemcitabine plus cisplatin in muscle‐invasive urothelial carcinoma of the bladder
Author(s) -
Dash Atreya,
Pettus Joseph A.,
Herr Harry W.,
Bochner Bernard H.,
Dalbagni Guido,
Donat S. Machele,
Russo Paul,
Boyle Mary G.,
Milowsky Matthew I.,
Bajorin Dean F.
Publication year - 2008
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.23848
Subject(s) - medicine , gemcitabine , cystectomy , neoadjuvant therapy , bladder cancer , vinblastine , regimen , cisplatin , oncology , urology , chemotherapy , cancer , breast cancer
BACKGROUND. Neoadjuvant cisplatin‐based chemotherapy improves survival in muscle‐invasive urothelial cancer, with MVAC (methotrexate, vinblastine, doxorubicin and cisplatin) considered the standard regimen. Gemcitabine plus cisplatin (GC) has similar efficacy and less toxicity than MVAC in metastatic disease, but is untested as neoadjuvant treatment. METHODS. The authors retrospectively evaluated patients with muscle‐invasive urothelial carcinoma who received neoadjuvant GC before radical cystectomy between November 2000 and December 2006 at Memorial Sloan‐Kettering Cancer Center. Post‐therapy pathological downstaging to either residual disease at cystectomy (pT0) or no residual muscle‐invasion (